This website is intended for healthcare professionals only.
TREATMENT STRATEGY IN mPaCa: EXTENDING THE CONTINUUM OF CARE?
Prof. Gerald Prager MD, PhD Director of the GI Cancer Program of the Department of Medical Oncology, Medical University of Vienna and Comprehensive Cancer Center, Vienna
This webinar focuses on the importance of planning the patient’s treatment sequence from the start - to factor in 2L therapy when choosing 1L options – in order to optimize and extend the continuum of care. An interactive clinical patient case is presented throughout the webinar to further highlight the need for treatment planning.
Key points covered
This webinar highlights the challenges faced when treating mPACA and the need for treatment planning. It covers the following kep points:
While both Gem + nabP and FOLFIRINOX are the preferred 1L treatment option, only Nal-IRI + 5-FU/LV is currently recommended as 2L option in mPaCa.
Nal-IRI + 5-FU/LV can only be given post-gemcitabine; it is therefore important to factor 2L from the start when choosing 1L treatment to ensure the best possible prognosis.
An interactive case is also presented throughout the webinar to highlight the important of treatment planning
Webinar Replay
Featured Speakers
Professor Gerald Prager
Prof Prager is the Director of the GI Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center, Vienna. He leads the Unit for Precision Medicine in Cancer and is an Associate Professor of Medicine, Board Certified for Internal Medicine, Hematology, and Medical Oncology. Prof Prager graduated from the Medical School of the University of Vienna and completed his postdoctoral training at the University of California, San Diego, USA and was a Visiting Professor at the Norris Cancer Center, University of Southern California, Los Angeles, USA in 2011. Prof Prager’s main research interests focus on translational research and (tumor-) angiogenesis and his works have been honored by more than 20 international awards and published in highly renowned international journals. Prof Prager is also a member of the ESMO Scientific Committee.
